Singapore: IHH leads Series A round for Lucence

Cancer-screening company Lucence has grabbed attention by nabbing IHH Healthcare as a minority investor in its US$20m Series A funding. “Liquid biopsy is a game-changer in our endeavour to provide cancer patients with better, value-driven outcomes through precise treatment selections and more affordable care,” said IHH chief executive designate Kelvin Loh. He went on to…

You must be a HMI Subscriber to view this content. Please log in or subscribe below.

Subscribe Now »